- Risankizumab, sold
under the
brand name
Skyrizi, is a
humanized monoclonal antibody used for the
treatment of
plaque psoriasis,
psoriatic arthritis, Crohn's...
- Crohn's disease,
plaque psoriasis, and
ulcerative colitis. It
developed Skyrizi ($7.8 billion in 2023 revenues), an interleukin-23 (IL-23)
inhibitor also...
-
human PDGFRB neovascular age-related
macular degeneration Risankizumab Skyrizi mab
humanized IL-23A Y Crohn's disease, psoriasis,
psoriatic arthritis...
- 1450–1461. doi:10.1053/j.gastro.2020.01.006. PMC 7175923. PMID 31945371. "
Skyrizi- risankizumab-rzaa kit". DailyMed. 18 June 2024.
Retrieved 2
November 2024...
- PMID 38284163. Brooks,
Abigail (18 June 2024). "FDA
Approves Risankizumab (
Skyrizi) for
Ulcerative Colitis". HCP Live.
Retrieved 2
November 2024. Lankford...
